CancerDrs

Head and Neck Cancer clinical trials in California

97 actively recruiting head and neck cancer trials at 69 sites across California.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 3 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 2, Phase 3 Recruiting NIH

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins i…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT01810913
Sites in California:
  • Sutter Cancer Centers Radiation Oncology Services-Auburn — Auburn, California
  • Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
  • Sutter Cancer Centers Radiation Oncology Services-Cameron Park — Cameron Park, California
  • Mercy San Juan Medical Center — Carmichael, California
  • UC San Diego Health System - Encinitas — Encinitas, California
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement (recurrent) a…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06589804
Sites in California:
  • Fremont - Rideout Cancer Center — Marysville, California
  • VA Palo Alto Health Care System — Palo Alto, California
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Academic/Other

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy s…

Sponsor: NRG Oncology
NCT ID: NCT04333537
Sites in California:
  • City of Hope Comprehensive Cancer Center — Duarte, California
  • UC San Diego Moores Cancer Center — La Jolla, California
  • Stanford Cancer Institute Palo Alto — Palo Alto, California
  • University of California Davis Comprehensive Cancer Center — Sacramento, California
  • UC San Diego Medical Center - Hillcrest — San Diego, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent disease.

Sponsor: Merus B.V.
NCT ID: NCT06496178
Sites in California:
  • Site 82 — Duarte, California
  • Site 25 — La Jolla, California
  • Site 173 — Orange, California
  • Site 28 — Palo Alto, California
  • Site 127 — Sacramento, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refract…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07276399
Sites in California:
  • Providence St Jude Medical Center — Fullerton, California
  • Scripps Health — La Jolla, California
  • Valkyrie Clinical Trials — Los Angeles, California
  • Valkyrie Clinical Trials Murrieta — Murrieta, California
  • University Of California - Davis — Sacramento, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.

Sponsor: Merus B.V.
NCT ID: NCT06525220
Sites in California:
  • Site 36 — La Jolla, California
  • Site 27 — Los Angeles, California
  • Site 16 — Palo Alto, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with Head and Neck Squamous Cell Carcinoma (HNSCC)

Sponsor: GlaxoSmithKline
NCT ID: NCT06256588
Sites in California:
  • GSK Investigational Site — Los Angeles, California
  • GSK Investigational Site — Solvang, California
  • GSK Investigational Site — Stockton, California
  • GSK Investigational Site — Torrance, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is …

Sponsor: AVEO Pharmaceuticals, Inc.
NCT ID: NCT06064877
Sites in California:
  • University of California Los Angeles — Los Angeles, California
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1

An open-label, controlled, multi-site, interventional, 2-arm, Phase II/III trial of BNT113 in combination with pembrolizumab vs pembrolizumab monotherapy as first line treatment in patients with unresectable recurrent or metastatic HPV16+ …

Sponsor: BioNTech SE
NCT ID: NCT04534205
Sites in California:
  • California Research Institute — Los Angeles, California
  • UCLA Cancer Care — Los Angeles, California
  • Stanford Cancer Institute — Palo Alto, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.

This is a multi-site, open-label, non-randomized, single dose study to assess the clinical utility of \[¹⁸F\]FAPI-74 PET/CT in the detection of metastatic disease in individuals with pathologically confirmed gastric, gastroesophageal junct…

Sponsor: SOFIE
NCT ID: NCT07217704
Sites in California:
  • Helios CR Inc./RadNet — Cerritos, California
  • City of Hope National Cancer Center — Duarte, California
  • Hoag Memorial Hospital — Irvine, California
  • UCLA — Los Angeles, California
  • Stanford University — Stanford, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd) in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have experienced disease progression following tre…

Sponsor: Daiichi Sankyo
NCT ID: NCT06644781
Sites in California:
  • Providence Medical Foundation — Fullerton, California
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers

Arm 1 ( Phase 2/3 Run in ): PRV111: Topical Locoregional Delivery Placed Over the Tumor Region Primary Endpoint: Overall Response Rate (ORR) Primary Objective: Demonstrate the safety and efficacy of PRV111 in patients with Carcinoma in Sit…

Sponsor: Privo Technologies
NCT ID: NCT05893888
Sites in California:
  • City of Hope National Medical Center — Duarte, California
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-ra…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT02734537
Sites in California:
  • Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
  • Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
  • Mercy Cancer Center - Carmichael — Carmichael, California
  • Mercy San Juan Medical Center — Carmichael, California
  • Mercy Cancer Center - Elk Grove — Elk Grove, California
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05136196
Sites in California:
  • Tower Cancer Research Foundation — Beverly Hills, California
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
  • The Angeles Clinic and Research Institute - West Los Angeles Office — Los Angeles, California
  • Cedars-Sinai Medical Center — Los Angeles, California
  • UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma …

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04671667
Sites in California:
  • Kaiser Permanente-Anaheim — Anaheim, California
  • Kaiser Permanente-Bellflower — Bellflower, California
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
  • UC San Diego Moores Cancer Center — La Jolla, California
  • Kaiser Permanente Los Angeles Medical Center — Los Angeles, California
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

This phase II trial compares the effectiveness of adding BMX-001 to usual symptom management versus usual symptom management alone for reducing oral mucositis in patients who are receiving chemoradiation for head and neck cancer. Oral muco…

Sponsor: NRG Oncology
NCT ID: NCT06532279
Sites in California:
  • Keck Medicine of USC Buena Park — Buena Park, California
  • UC San Diego Health System - Encinitas — Encinitas, California
  • UC San Diego Moores Cancer Center — La Jolla, California
  • Los Angeles General Medical Center — Los Angeles, California
  • USC / Norris Comprehensive Cancer Center — Los Angeles, California
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

This phase II trial compares the effect of usual treatment of docetaxel chemotherapy plus trastuzumab, to ado-emtansine (T-DM1) in patients with HER2-postive salivary gland cancer that has come back (recurrent), that has spread from where …

Sponsor: NRG Oncology
NCT ID: NCT05408845
Sites in California:
  • City of Hope Comprehensive Cancer Center — Duarte, California
  • Kaiser Permanente Dublin — Dublin, California
  • Kaiser Permanente-Fremont — Fremont, California
  • Kaiser Permanente Fresno Orchard Plaza — Fresno, California
  • Kaiser Permanente-Fresno — Fresno, California
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

This phase II trial tests effects of nivolumab in combination with chemotherapy drugs prior to radiation therapy patients with nasopharyngeal carcinoma (NPC). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06064097
Sites in California:
  • Kaiser Permanente Downey Medical Center — Downey, California
  • Loma Linda University Medical Center — Loma Linda, California
  • Children's Hospital Los Angeles — Los Angeles, California
  • Valley Children's Hospital — Madera, California
  • UCSF Benioff Children's Hospital Oakland — Oakland, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with…

Sponsor: Eli Lilly and Company
NCT ID: NCT05768139
Sites in California:
  • Ellison Clinic at Saint John's — Los Angeles, California
  • UCSF Medical Center at Mission Bay — San Francisco, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.

Sponsor: DualityBio Inc.
NCT ID: NCT05914116
Sites in California:
  • Research Site 125 — Los Angeles, California
  • Research Site 133 — Los Angeles, California
  • Research Site 103 — Los Angeles, California
  • Research Site 128 — Santa Monica, California
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. The cancers types ar…

Sponsor: Vyriad, Inc.
NCT ID: NCT04291105
Sites in California:
  • City of Hope Medical Center — Durate, California
  • USC Norris Comprehensive Cancer Center — Los Angeles, California
  • HOAG Memorial Hospital Presbyterian — Newport Beach, California
  • Saint John's Health Center - John Wayne Cancer Institute (JWCI) — Santa Monica, California
  • Stanford Health Care — Stanford, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been com…

Sponsor: Merus B.V.
NCT ID: NCT03526835
Sites in California:
  • UCSD — La Jolla, California
  • USC Norris Comprehensive Cancer Center — Los Angeles, California
  • Sharp Healthcare — San Diego, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies …

Sponsor: Institut de Recherches Internationales Servier
NCT ID: NCT05786924
Sites in California:
  • The Angeles clinic - A cedars SINAI AFFILIATE — Los Angeles, California
  • USC Norris Comprehensive Cancer Center — Los Angeles, California
  • University of California, San Francisco (UCSF) — San Francisco, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a monotherapy…

Sponsor: Avenzo Therapeutics, Inc.
NCT ID: NCT07038343
Sites in California:
  • Avenzo Therapeutics Recruiting Site — Los Angeles, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-ri…

Sponsor: Marengo Therapeutics, Inc.
NCT ID: NCT05592626
Sites in California:
  • Loma Linda University Cancer Center — Loma Linda, California
  • UC Davis Comprehensive Cancer Center — Sacramento, California
View on ClinicalTrials.gov →

Showing 25 of 97 trials with sites in California. See all head and neck cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-07-07